Ex-Immunomedics CEO takes the wheel at Danish ADC player.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      DENMARK
    • Abstract:
      On the heels of a $62 million funding round, Denmark's Adcendo has a new CEO: Michael Pehl, formerly Celgene's oncology chief and CEO of Immunomedics, the company behind Gilead's potential blockbuster breast cancer drug Trodelvy. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)